Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Cancer

January 16, 2019 1:46 PM UTC

Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in vitro testing of the top hit, yielded a naphthalenone-based compound that inhibited Hsp90 with an IC50 of 29.5 nM. In a human glioblastoma cell line, the compound decreased growth and motility and increased levels of apoptotic markers compared with vehicle. In a xenograft mouse model of glioblastoma, the compound decreased tumor growth. Next steps could include testing the compound in patient-derived xenograft (PDX) mouse model of glioblastoma.

Soligenix Inc. has hypericin, a topical phototherapeutic agent that inhibits Hsp90, in Phase III testing for cutaneous T cell lymphoma (CTCL)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article